Loading…

Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt

Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other ex...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and translational medicine 2022-09, Vol.12 (9), p.e1041-n/a
Main Authors: Agarwal, Sakshi, Kaur, Simrandeep, Asuru, Tejeswara Rao, Joshi, Garima, Shrimali, Nishith M, Singh, Anamika, Singh, Oinam Ningthemmani, Srivastva, Puneet, Shrivastava, Tripti, Vrati, Sudhanshu, Surjit, Milan, Guchhait, Prasenjit
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page n/a
container_issue 9
container_start_page e1041
container_title Clinical and translational medicine
container_volume 12
creator Agarwal, Sakshi
Kaur, Simrandeep
Asuru, Tejeswara Rao
Joshi, Garima
Shrimali, Nishith M
Singh, Anamika
Singh, Oinam Ningthemmani
Srivastva, Puneet
Shrivastava, Tripti
Vrati, Sudhanshu
Surjit, Milan
Guchhait, Prasenjit
description Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other extracellular matrix, and accumulation of fluid in alveoli lead to reduced blood-gas barrier permeability and exchange of O2, causing a condition called hypoxemia or decreased oxygen pressure saturation (SpO2) in COVID-19.2 With a focus on our investigation to inhibit viral infection and rescue lung pathogenesis in COVID-19, we tested the effect of alpha-ketoglutarate (αKG), a common metabolite of the Krebs cycle, in SARS CoV-2-infected animals. Recently, we reported that αKG, a co-factor of prolyl hydroxylase 2(PHD2), augmented the prolyl hydroxylation activity of the enzyme and significantly degraded its substrates such as phosphorylated-Akt (pAkt)3 and HIF1α / HIF2α.4 Dietary supplementation of αKG significantly reduced pro-inflammatory and pro-thrombotic responses of leukocytes and platelets in conjunction with downmodulation of pAkt in mice.3 Studies have reported the usage of αKG to improve human health. Administration of αKG in blood cardioplegia improved myocardial protection in patients with heart surgery.5 Dietary supplementation of αKG along with vitamin delayed human aging.6 It is now known that (1) SARS CoV-2 employs Akt signalling for propagation in its host7 and (2) pAkt promotes platelet activation and thrombosis as well as leukocyte activation and inflammation in SARS CoV-2-infected animals.3 We, therefore, investigated whether (1) αKG could inhibit SARS CoV-2 replication by downmodulating pAkt in vitro and in vivo, and (2) dietary supplementation of the metabolite could rescue the lung pathogenesis to restore normal O2 saturation in infected animals. SEE PDF] In conclusion, our study describes that αKG significantly inhibits SARS CoV-2 replication and reduces inflammation, thrombosis and apoptotic cell death in the lungs to restore normal SpO2 saturation in infected animals without affecting the anti-viral response of CD4 and CD8 T cells, and IgG. [...]our study strongly suggests a potential use of this metabolite as one of the first-line therapeutics for COVID-19.
doi_str_mv 10.1002/ctm2.1041
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_773281bd149944569fc950ff1820b199</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_773281bd149944569fc950ff1820b199</doaj_id><sourcerecordid>2715792819</sourcerecordid><originalsourceid>FETCH-LOGICAL-d3241-5c810af138dfe5d553f0a3279e45b3850e158e6176d23ad1605ffe03e6b081773</originalsourceid><addsrcrecordid>eNpdks9u1DAQxiMEolXpgTewxIXLUo8dJ_EFabX8q1RUiRaulpOMs9564yV2QHvroQ_AM_Ik2GxBFF88-ubzzzOjKYrnQF8Bpeysi1uWohIeFceMUlgAZ9Xjf-Kj4jSEDU2nKaWs2dPiiFfAAGp5XNy9sRj1tCfa7db65-2PG4x-cHPSdERix7VtbQzkavnpiqz8l-RgSTXYRetHoseeTBi6GUNWnd5iT9w8DoFEnzPRT0guGQk6zomY37T7P1g7DmS3vInPiidGu4Cn9_dJ8fnd2-vVh8XF5fvz1fJi0XNWwkJ0DVBtgDe9QdELwQ3VnNUSS9HyRlAE0WAFddUzrnuoqDAGKceqpQ3UNT8pzg_c3uuN2k12mzpXXlv1W_DToPQUbedQJTdroO0hjawsRSVNJwU1BhpGW5AysV4fWLu5TU13OMZJuwfQh5nRrtXgvylZNiWrcjEv7wGT_5rmF9XWhg6d0yP6OShWg6hlKiL_9eI_68bP05hGlVwVbVjNeAaeHVzfrcP930qAqrwnKu-JynuiVtcfWQ74L4oosgY</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2760827237</pqid></control><display><type>article</type><title>Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt</title><source>Wiley-Blackwell Open Access Collection</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central (PMC)</source><source>Coronavirus Research Database</source><creator>Agarwal, Sakshi ; Kaur, Simrandeep ; Asuru, Tejeswara Rao ; Joshi, Garima ; Shrimali, Nishith M ; Singh, Anamika ; Singh, Oinam Ningthemmani ; Srivastva, Puneet ; Shrivastava, Tripti ; Vrati, Sudhanshu ; Surjit, Milan ; Guchhait, Prasenjit</creator><creatorcontrib>Agarwal, Sakshi ; Kaur, Simrandeep ; Asuru, Tejeswara Rao ; Joshi, Garima ; Shrimali, Nishith M ; Singh, Anamika ; Singh, Oinam Ningthemmani ; Srivastva, Puneet ; Shrivastava, Tripti ; Vrati, Sudhanshu ; Surjit, Milan ; Guchhait, Prasenjit</creatorcontrib><description>Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other extracellular matrix, and accumulation of fluid in alveoli lead to reduced blood-gas barrier permeability and exchange of O2, causing a condition called hypoxemia or decreased oxygen pressure saturation (SpO2) in COVID-19.2 With a focus on our investigation to inhibit viral infection and rescue lung pathogenesis in COVID-19, we tested the effect of alpha-ketoglutarate (αKG), a common metabolite of the Krebs cycle, in SARS CoV-2-infected animals. Recently, we reported that αKG, a co-factor of prolyl hydroxylase 2(PHD2), augmented the prolyl hydroxylation activity of the enzyme and significantly degraded its substrates such as phosphorylated-Akt (pAkt)3 and HIF1α / HIF2α.4 Dietary supplementation of αKG significantly reduced pro-inflammatory and pro-thrombotic responses of leukocytes and platelets in conjunction with downmodulation of pAkt in mice.3 Studies have reported the usage of αKG to improve human health. Administration of αKG in blood cardioplegia improved myocardial protection in patients with heart surgery.5 Dietary supplementation of αKG along with vitamin delayed human aging.6 It is now known that (1) SARS CoV-2 employs Akt signalling for propagation in its host7 and (2) pAkt promotes platelet activation and thrombosis as well as leukocyte activation and inflammation in SARS CoV-2-infected animals.3 We, therefore, investigated whether (1) αKG could inhibit SARS CoV-2 replication by downmodulating pAkt in vitro and in vivo, and (2) dietary supplementation of the metabolite could rescue the lung pathogenesis to restore normal O2 saturation in infected animals. SEE PDF] In conclusion, our study describes that αKG significantly inhibits SARS CoV-2 replication and reduces inflammation, thrombosis and apoptotic cell death in the lungs to restore normal SpO2 saturation in infected animals without affecting the anti-viral response of CD4 and CD8 T cells, and IgG. [...]our study strongly suggests a potential use of this metabolite as one of the first-line therapeutics for COVID-19.</description><identifier>ISSN: 2001-1326</identifier><identifier>EISSN: 2001-1326</identifier><identifier>DOI: 10.1002/ctm2.1041</identifier><identifier>PMID: 36121179</identifier><language>eng</language><publisher>Heidelberg: John Wiley &amp; Sons, Inc</publisher><subject>Aging ; Blood platelets ; Coronaviruses ; COVID-19 ; DNA methylation ; Enzymes ; Heart surgery ; Infections ; Inflammation ; Investigations ; Letter to the Editor ; Lungs ; Pathogenesis ; Proteins ; Severe acute respiratory syndrome coronavirus 2 ; Thrombosis ; Viral infections</subject><ispartof>Clinical and translational medicine, 2022-09, Vol.12 (9), p.e1041-n/a</ispartof><rights>2022 The Authors. published by John Wiley &amp; Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</rights><rights>2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2760827237/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2760827237?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,11541,25731,27901,27902,36989,36990,38493,43871,44566,46027,46451,53766,53768,74155,74869</link.rule.ids></links><search><creatorcontrib>Agarwal, Sakshi</creatorcontrib><creatorcontrib>Kaur, Simrandeep</creatorcontrib><creatorcontrib>Asuru, Tejeswara Rao</creatorcontrib><creatorcontrib>Joshi, Garima</creatorcontrib><creatorcontrib>Shrimali, Nishith M</creatorcontrib><creatorcontrib>Singh, Anamika</creatorcontrib><creatorcontrib>Singh, Oinam Ningthemmani</creatorcontrib><creatorcontrib>Srivastva, Puneet</creatorcontrib><creatorcontrib>Shrivastava, Tripti</creatorcontrib><creatorcontrib>Vrati, Sudhanshu</creatorcontrib><creatorcontrib>Surjit, Milan</creatorcontrib><creatorcontrib>Guchhait, Prasenjit</creatorcontrib><title>Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt</title><title>Clinical and translational medicine</title><description>Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other extracellular matrix, and accumulation of fluid in alveoli lead to reduced blood-gas barrier permeability and exchange of O2, causing a condition called hypoxemia or decreased oxygen pressure saturation (SpO2) in COVID-19.2 With a focus on our investigation to inhibit viral infection and rescue lung pathogenesis in COVID-19, we tested the effect of alpha-ketoglutarate (αKG), a common metabolite of the Krebs cycle, in SARS CoV-2-infected animals. Recently, we reported that αKG, a co-factor of prolyl hydroxylase 2(PHD2), augmented the prolyl hydroxylation activity of the enzyme and significantly degraded its substrates such as phosphorylated-Akt (pAkt)3 and HIF1α / HIF2α.4 Dietary supplementation of αKG significantly reduced pro-inflammatory and pro-thrombotic responses of leukocytes and platelets in conjunction with downmodulation of pAkt in mice.3 Studies have reported the usage of αKG to improve human health. Administration of αKG in blood cardioplegia improved myocardial protection in patients with heart surgery.5 Dietary supplementation of αKG along with vitamin delayed human aging.6 It is now known that (1) SARS CoV-2 employs Akt signalling for propagation in its host7 and (2) pAkt promotes platelet activation and thrombosis as well as leukocyte activation and inflammation in SARS CoV-2-infected animals.3 We, therefore, investigated whether (1) αKG could inhibit SARS CoV-2 replication by downmodulating pAkt in vitro and in vivo, and (2) dietary supplementation of the metabolite could rescue the lung pathogenesis to restore normal O2 saturation in infected animals. SEE PDF] In conclusion, our study describes that αKG significantly inhibits SARS CoV-2 replication and reduces inflammation, thrombosis and apoptotic cell death in the lungs to restore normal SpO2 saturation in infected animals without affecting the anti-viral response of CD4 and CD8 T cells, and IgG. [...]our study strongly suggests a potential use of this metabolite as one of the first-line therapeutics for COVID-19.</description><subject>Aging</subject><subject>Blood platelets</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>DNA methylation</subject><subject>Enzymes</subject><subject>Heart surgery</subject><subject>Infections</subject><subject>Inflammation</subject><subject>Investigations</subject><subject>Letter to the Editor</subject><subject>Lungs</subject><subject>Pathogenesis</subject><subject>Proteins</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Thrombosis</subject><subject>Viral infections</subject><issn>2001-1326</issn><issn>2001-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdks9u1DAQxiMEolXpgTewxIXLUo8dJ_EFabX8q1RUiRaulpOMs9564yV2QHvroQ_AM_Ik2GxBFF88-ubzzzOjKYrnQF8Bpeysi1uWohIeFceMUlgAZ9Xjf-Kj4jSEDU2nKaWs2dPiiFfAAGp5XNy9sRj1tCfa7db65-2PG4x-cHPSdERix7VtbQzkavnpiqz8l-RgSTXYRetHoseeTBi6GUNWnd5iT9w8DoFEnzPRT0guGQk6zomY37T7P1g7DmS3vInPiidGu4Cn9_dJ8fnd2-vVh8XF5fvz1fJi0XNWwkJ0DVBtgDe9QdELwQ3VnNUSS9HyRlAE0WAFddUzrnuoqDAGKceqpQ3UNT8pzg_c3uuN2k12mzpXXlv1W_DToPQUbedQJTdroO0hjawsRSVNJwU1BhpGW5AysV4fWLu5TU13OMZJuwfQh5nRrtXgvylZNiWrcjEv7wGT_5rmF9XWhg6d0yP6OShWg6hlKiL_9eI_68bP05hGlVwVbVjNeAaeHVzfrcP930qAqrwnKu-JynuiVtcfWQ74L4oosgY</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Agarwal, Sakshi</creator><creator>Kaur, Simrandeep</creator><creator>Asuru, Tejeswara Rao</creator><creator>Joshi, Garima</creator><creator>Shrimali, Nishith M</creator><creator>Singh, Anamika</creator><creator>Singh, Oinam Ningthemmani</creator><creator>Srivastva, Puneet</creator><creator>Shrivastava, Tripti</creator><creator>Vrati, Sudhanshu</creator><creator>Surjit, Milan</creator><creator>Guchhait, Prasenjit</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202209</creationdate><title>Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt</title><author>Agarwal, Sakshi ; Kaur, Simrandeep ; Asuru, Tejeswara Rao ; Joshi, Garima ; Shrimali, Nishith M ; Singh, Anamika ; Singh, Oinam Ningthemmani ; Srivastva, Puneet ; Shrivastava, Tripti ; Vrati, Sudhanshu ; Surjit, Milan ; Guchhait, Prasenjit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d3241-5c810af138dfe5d553f0a3279e45b3850e158e6176d23ad1605ffe03e6b081773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aging</topic><topic>Blood platelets</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>DNA methylation</topic><topic>Enzymes</topic><topic>Heart surgery</topic><topic>Infections</topic><topic>Inflammation</topic><topic>Investigations</topic><topic>Letter to the Editor</topic><topic>Lungs</topic><topic>Pathogenesis</topic><topic>Proteins</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Thrombosis</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Agarwal, Sakshi</creatorcontrib><creatorcontrib>Kaur, Simrandeep</creatorcontrib><creatorcontrib>Asuru, Tejeswara Rao</creatorcontrib><creatorcontrib>Joshi, Garima</creatorcontrib><creatorcontrib>Shrimali, Nishith M</creatorcontrib><creatorcontrib>Singh, Anamika</creatorcontrib><creatorcontrib>Singh, Oinam Ningthemmani</creatorcontrib><creatorcontrib>Srivastva, Puneet</creatorcontrib><creatorcontrib>Shrivastava, Tripti</creatorcontrib><creatorcontrib>Vrati, Sudhanshu</creatorcontrib><creatorcontrib>Surjit, Milan</creatorcontrib><creatorcontrib>Guchhait, Prasenjit</creatorcontrib><collection>Wiley-Blackwell Open Access Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Clinical and translational medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Agarwal, Sakshi</au><au>Kaur, Simrandeep</au><au>Asuru, Tejeswara Rao</au><au>Joshi, Garima</au><au>Shrimali, Nishith M</au><au>Singh, Anamika</au><au>Singh, Oinam Ningthemmani</au><au>Srivastva, Puneet</au><au>Shrivastava, Tripti</au><au>Vrati, Sudhanshu</au><au>Surjit, Milan</au><au>Guchhait, Prasenjit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt</atitle><jtitle>Clinical and translational medicine</jtitle><date>2022-09</date><risdate>2022</risdate><volume>12</volume><issue>9</issue><spage>e1041</spage><epage>n/a</epage><pages>e1041-n/a</pages><issn>2001-1326</issn><eissn>2001-1326</eissn><abstract>Unlike with other respiratory viral infections, symptoms of COVID-19 are very heterogeneous ranging from minimal to Acute Respiratory Distress Syndrome (ARDS).1 Elevated intravascular clots, accumulation of leukocytes including neutrophils and macrophages, deposition of collagen, mucus, and other extracellular matrix, and accumulation of fluid in alveoli lead to reduced blood-gas barrier permeability and exchange of O2, causing a condition called hypoxemia or decreased oxygen pressure saturation (SpO2) in COVID-19.2 With a focus on our investigation to inhibit viral infection and rescue lung pathogenesis in COVID-19, we tested the effect of alpha-ketoglutarate (αKG), a common metabolite of the Krebs cycle, in SARS CoV-2-infected animals. Recently, we reported that αKG, a co-factor of prolyl hydroxylase 2(PHD2), augmented the prolyl hydroxylation activity of the enzyme and significantly degraded its substrates such as phosphorylated-Akt (pAkt)3 and HIF1α / HIF2α.4 Dietary supplementation of αKG significantly reduced pro-inflammatory and pro-thrombotic responses of leukocytes and platelets in conjunction with downmodulation of pAkt in mice.3 Studies have reported the usage of αKG to improve human health. Administration of αKG in blood cardioplegia improved myocardial protection in patients with heart surgery.5 Dietary supplementation of αKG along with vitamin delayed human aging.6 It is now known that (1) SARS CoV-2 employs Akt signalling for propagation in its host7 and (2) pAkt promotes platelet activation and thrombosis as well as leukocyte activation and inflammation in SARS CoV-2-infected animals.3 We, therefore, investigated whether (1) αKG could inhibit SARS CoV-2 replication by downmodulating pAkt in vitro and in vivo, and (2) dietary supplementation of the metabolite could rescue the lung pathogenesis to restore normal O2 saturation in infected animals. SEE PDF] In conclusion, our study describes that αKG significantly inhibits SARS CoV-2 replication and reduces inflammation, thrombosis and apoptotic cell death in the lungs to restore normal SpO2 saturation in infected animals without affecting the anti-viral response of CD4 and CD8 T cells, and IgG. [...]our study strongly suggests a potential use of this metabolite as one of the first-line therapeutics for COVID-19.</abstract><cop>Heidelberg</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>36121179</pmid><doi>10.1002/ctm2.1041</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2001-1326
ispartof Clinical and translational medicine, 2022-09, Vol.12 (9), p.e1041-n/a
issn 2001-1326
2001-1326
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_773281bd149944569fc950ff1820b199
source Wiley-Blackwell Open Access Collection; Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central (PMC); Coronavirus Research Database
subjects Aging
Blood platelets
Coronaviruses
COVID-19
DNA methylation
Enzymes
Heart surgery
Infections
Inflammation
Investigations
Letter to the Editor
Lungs
Pathogenesis
Proteins
Severe acute respiratory syndrome coronavirus 2
Thrombosis
Viral infections
title Dietary alpha‐ketoglutarate inhibits SARS CoV‐2 infection and rescues inflamed lungs to restore O2 saturation by inhibiting pAkt
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T14%3A27%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dietary%20alpha%E2%80%90ketoglutarate%20inhibits%20SARS%20CoV%E2%80%902%20infection%20and%20rescues%20inflamed%20lungs%20to%20restore%20O2%20saturation%20by%20inhibiting%20pAkt&rft.jtitle=Clinical%20and%20translational%20medicine&rft.au=Agarwal,%20Sakshi&rft.date=2022-09&rft.volume=12&rft.issue=9&rft.spage=e1041&rft.epage=n/a&rft.pages=e1041-n/a&rft.issn=2001-1326&rft.eissn=2001-1326&rft_id=info:doi/10.1002/ctm2.1041&rft_dat=%3Cproquest_doaj_%3E2715792819%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-d3241-5c810af138dfe5d553f0a3279e45b3850e158e6176d23ad1605ffe03e6b081773%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2760827237&rft_id=info:pmid/36121179&rfr_iscdi=true